Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Askgaard D. S., Wilcke T., Døssing M. Hepatotoxicity caused by the combined action of isoniazid and rifampicin. Thorax. 1995 Feb;50(2):213–214. doi: 10.1136/thx.50.2.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Citron K. M., Thomas G. O. Ocular toxicity from ethambutol. Thorax. 1986 Oct;41(10):737–739. doi: 10.1136/thx.41.10.737. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Girling D. J. Adverse effects of antituberculosis drugs. Drugs. 1982 Jan-Feb;23(1-2):56–74. doi: 10.2165/00003495-198223010-00003. [DOI] [PubMed] [Google Scholar]
- Humphries M. J., Byfield S. P., Darbyshire J. H., Davies P. D., Nunn A. J., Citron K. M., Fox W. Deaths occurring in newly notified patients with pulmonary tuberculosis in England and Wales. Br J Dis Chest. 1984 Apr;78(2):149–158. [PubMed] [Google Scholar]
- Kopanoff D. E., Snider D. E., Jr, Caras G. J. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978 Jun;117(6):991–1001. doi: 10.1164/arrd.1978.117.6.991. [DOI] [PubMed] [Google Scholar]
- Lal S., Singhal S. N., Burley D. M., Crossley G. Effect of rifampicin and isoniazid on liver function. Br Med J. 1972 Jan 15;1(5793):148–150. doi: 10.1136/bmj.1.5793.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mitchell I., Wendon J., Fitt S., Williams R. Anti-tuberculous therapy and acute liver failure. Lancet. 1995 Mar 4;345(8949):555–556. doi: 10.1016/s0140-6736(95)90468-9. [DOI] [PubMed] [Google Scholar]
- Ormerod L. P., Prescott R. J. Inter-relations between relapses, drug regimens and compliance with treatment in tuberculosis. Respir Med. 1991 May;85(3):239–242. doi: 10.1016/s0954-6111(06)80087-9. [DOI] [PubMed] [Google Scholar]
- Riska N. Hepatitis cases in isoniazid treated groups and in a control group. Bull Int Union Tuberc. 1976;51(1):203–208. [PubMed] [Google Scholar]
- Snider D. E., Jr, Long M. W., Cross F. S., Farer L. S. Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Report of a United States Public Health Service Cooperative Trial. Am Rev Respir Dis. 1984 Apr;129(4):573–579. [PubMed] [Google Scholar]
- Türktaş H., Unsal M., Tülek N., Orü O. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. Tuber Lung Dis. 1994 Feb;75(1):58–60. doi: 10.1016/0962-8479(94)90104-X. [DOI] [PubMed] [Google Scholar]
- Whittington R. M. Fatal hepatotoxicity of anti-tubercular chemotherapy. Lancet. 1991 Oct 26;338(8774):1083–1084. doi: 10.1016/0140-6736(91)91943-o. [DOI] [PubMed] [Google Scholar]